• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OptimizeRx Sets Third Quarter Fiscal 2022 Conference Call for Tuesday, November 8 at 4:30 p.m. ET

By: OptimizeRx Corporation via GlobeNewswire
October 19, 2022 at 16:05 PM EDT

ROCHESTER, Mich., Oct. 19, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Tuesday, November 8, 2022, at 4:30 p.m. Eastern time to discuss its results for the third quarter, ended September 30, 2022. The financial results will be issued in a press release prior to the call.

OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:

Date:Tuesday, November 8, 2022
Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1577818&tp_key=c51f87e696
Toll Free:1-888-999-3182
International:1-848-280-6330
Conference ID:8072033
  

Please call the conference telephone number or log on to the web access link five minutes prior to the start time.

A replay of the call will remain available for 12 months via the Investors section of the OptimizeRx website at www.optimizerx.com/investors.  

About OptimizeRx
OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through the most intelligent technology platform embedded within a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on their medications. 

For more information, follow the Company on Twitter, LinkedIn or visit www.optimizerx.com.

Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.

OptimizeRx Contact 
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com

Media Relations Contact 
Kimberley Sirk, Media Relations Manager 
ksirk@optimizerx.com

Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com


Primary Logo

More News

View More
3 Dividend Stocks Raising Payouts—and Backing It Up With Results
August 10, 2025
Via MarketBeat
Tickers CLX SUN WFC
3 Stocks With Monopoly Power—and Minimal Competition
August 10, 2025
Via MarketBeat
Tickers ASML CPRT FICO
Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?
August 09, 2025
Via MarketBeat
Tickers RKLB
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
August 09, 2025
Via MarketBeat
Topics Government World Trade
Tickers HD KO LLY LOW
Now Is a Great Time to Buy Cheniere Energy: New High Expected
August 09, 2025
Via MarketBeat
Tickers LNG
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap